Previous close | 12.86 |
Open | 12.86 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's range | 12.86 - 12.86 |
52-week range | 7.40 - 13.60 |
Volume | |
Avg. volume | 52 |
Market cap | 1.666B |
Beta (5Y monthly) | 0.65 |
PE ratio (TTM) | 85.71 |
EPS (TTM) | 0.15 |
Earnings date | 14 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
KAWASAKI, Japan, April 30, 2024--PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President and CEO: Patrick C. Reid, hereinafter "PeptiDream") (Tokyo: 4587) today announced an expansion of its peptide discovery collaboration with Swiss-based Novartis Pharma AG ("hereinafter Novartis") (NYSE: NVS). Under the multi-program agreement, PeptiDream will use its proprietary Peptide Discovery Platform System ("PDPS®") technology to identify and optimize novel macrocyclic pepti
KAWASAKI, Japan, September 20, 2023--Combining the PeptiDream's expertise in the field of peptide-RI conjugates, with Genentech's powerful development and commercialization capabilities.
TOKYO & KAWASAKI, Japan, July 25, 2023--PeptiDream and Astellas plan to combine PeptiDream's peptide discovery technology with Astellas' capabilities to discover next-gen protein degraders.